Liprolog

Insulin lispro, the active ingredient in Liprolog, is a rapid‑acting insulin analog presented as a sterile solution for subcutaneous and intravenous use. It lowers blood glucose in patients with diabetes mellitus type 1 or type 2 by mimicking the body’s natural post‑meal insulin response. The formulation enables rapid absorption, helping achieve target glycaemic levels after meals.

GNH USA supplies Liprolog as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on quality assurance and regulatory compliance across EU and global markets.

Liprolog, a rapid‑acting insulin analog, is used to manage hyperglycaemia by providing fast‑acting insulin replacement in the diabetes treatment pathway and is indicated for patients requiring mealtime glucose control.

Diabetes mellitus type 1: Provides rapid insulin action to cover meals and correct basal‑insulin gaps, facilitating tight glycaemic control in insulin‑dependent patients. Diabetes mellitus type 2: Used as part of an intensive insulin regimen to manage post‑prandial glucose excursions when oral agents are insufficient.

The safety profile of Liprolog includes both frequent, generally mild reactions and rare, potentially serious events.

Common Side Effects: - Hypoglycaemia: symptomatic low blood glucose that may cause sweating, tremor, or confusion. - Injection site reactions: redness, swelling, or itching at the injection site. - Lipodystrophy: localized thickening or loss of subcutaneous fat with repeated injections.

Serious or Rare Side Effects: - Severe hypoglycaemia: loss of consciousness or seizures requiring assistance. - Allergic reactions: urticaria, angioedema, or anaphylaxis. - Hypokalemia: marked drop in serum potassium associated with rapid insulin action.

When prescribing Liprolog, clinicians should consider several precautionary measures to ensure safe and effective use. - Blood glucose monitoring: Perform frequent self‑monitoring to adjust dose and avoid hypoglycaemia. - Dose adjustment: Reduce dose during illness, reduced food intake, or increased physical activity. - Renal impairment: Use lower initial doses and monitor closely in patients with reduced kidney function. - Hypersensitivity: Discontinue if signs of allergic reaction such as rash or swelling appear. - Pregnancy and lactation: Evaluate risk‑benefit; insulin is generally preferred but data are limited for lispro. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake the vial.

Insulin lispro may interact with other medicines, altering its glucose‑lowering effect or increasing adverse reactions.

Major Interactions (Avoid): - Sulfonylureas and meglitinides: additive hypoglycaemic effect; may require dose reduction. - Beta‑blockers: can mask hypoglycaemia symptoms, necessitating closer glucose monitoring. - ACE inhibitors and ARBs: may potentiate insulin’s glucose‑lowering action, increasing hypoglycaemia risk.

Moderate Interactions (Monitor Closely): - Thiazide diuretics: may raise blood glucose, reducing insulin efficacy. - Oral contraceptives and hormone replacement therapy: can affect insulin sensitivity, requiring dose adjustments. - Alcohol: can cause unpredictable glucose fluctuations, especially when combined with rapid‑acting insulin.